Quest Diagnostics Revises FY23 Revenue Guidance To $9.12B-$9.22B Vs. Consensus Of $9.06B And Prior Guidance Of $8.93B-$9.08B, It Forecasts Adjusted EPS Of $8.50-$8.90 Vs. Consensus Of $8.69 And Prior Guidance Of $8.45-$8.95
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics has revised its FY23 revenue guidance to $9.12B-$9.22B, up from the prior guidance of $8.93B-$9.08B. The new guidance surpasses the consensus of $9.06B. The company also forecasts an adjusted EPS of $8.50-$8.90, compared to the consensus of $8.69 and prior guidance of $8.45-$8.95.
July 26, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quest Diagnostics has raised its FY23 revenue guidance, which is now above the consensus. The adjusted EPS forecast is also revised.
Quest Diagnostics has revised its FY23 revenue guidance upwards, which is a positive signal for investors. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100